Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06047379 |
|
Recruitment Status :
Recruiting
First Posted : September 21, 2023
Last Update Posted : February 14, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diffuse Astrocytoma, IDH-Mutant Glioblastoma, IDH-wildtype Brain Metastases, Adult Cervical Cancer Colorectal Cancer Esophageal Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Gastroesophageal Junction Adenocarcinoma Head and Neck Squamous Cell Carcinoma Melanoma Merkel Cell Carcinoma Microsatellite Instability-High Solid Malignant Tumor Mismatch Repair Deficient Solid Malignant Tumor Microsatellite Instability-High Colorectal Cancer Mismatch Repair Deficient Colorectal Cancer Non-small Cell Lung Cancer Renal Cell Carcinoma Small Cell Lung Cancer Squamous Cell Carcinoma Urothelial Carcinoma | Drug: NEO212 Oral Capsule Drug: Ipilimumab Drug: Pembrolizumab Drug: Nivolumab Drug: Regorafenib Drug: Carboplatin Drug: Paclitaxel Drug: FOLFIRI Protocol Drug: Bevacizumab | Phase 1 Phase 2 |
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled brain metastasis. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Phase 1 is a standard cohort dose escalation 3+3 design with a modified Fibonacci dose escalation used to determine the maximum tolerated dose to select a recommended Phase 2 dose (RP2D) for Phase 2a and Phase 2b. The initial dose of NEO212 will be 170mg and the dose will increase in successive cohorts (220, 400, 610, 810, and 1,000mg) until a MTD is reached and a RP2D is selected. There will be up to 42 patients enrolled in Phase 1. In the event two DLTs are experienced in any cohort, a dose de-escalation cohort will be followed (with half of the dose increase from the previous cohort) to determine the MTD/RP2D.
Phase 2a is a safety run-in study with a standard 3+3 design used to confirm the safety of the MTD/RP2D of NEO212 when given in combination with select SOC regimens for patients with uncontrolled brain metastasis. There will be up to 12 patients enrolled into each combination regimen to confirm safety. One dose below the NEO212 MTD/RP2D Cohort Dose will be administered as a starting dose to establish safety (3+3), before moving to Phase 2b with the MTD/RP2D (3+3). In the event that two DLTs are experienced for patient receiving the MTD/RP2D in combination with SOC, the dose de-escalation cohort will be expanded to determine the MTD for a newly established Phase 2b Treatment Group.
Phase 2b is a dose expansion study to assess efficacy of NEO212, at the MTD/RP2D in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype as a single Treatment Group. A second Treatment Group to study the MTD/RP2D of NEO212 in combination with select SOC regimens in patients with solid tumors and uncontrolled brain metastasis established in Phase 2a will be evaluated. Phase 2b will be initiated for patients with Astrocytoma IDH-mutant or Glioblastoma IDH-wildtype alongside Phase 2a. There will be up to 28 patients enrolled to have 27 evaluable patients enrolled in each Phase 2b Treatment Group.
For all phases of the study, NEO212 will be self-administered daily for days 1-5 of a 28-day treatment cycle.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 134 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors. |
| Actual Study Start Date : | November 1, 2023 |
| Estimated Primary Completion Date : | February 28, 2026 |
| Estimated Study Completion Date : | August 31, 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Phase 2a Safety Run-In - NEO212 and Ipilimumab
- Unresectable or metastatic melanoma with uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Ipilimumab - 3 mg/kg administered IV over 90 minutes every 3 weeks for a maximum of 3 doses per package insert. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Name: POH-TMZ Drug: Ipilimumab Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
Other Name: Yervoy |
|
Experimental: Phase 2a Safety Run-In - NEO212 and Pembrolizumab
The following primary cancers with uncontrolled metrastases to the brain:
NEO212 - Same as Arm 1. Pembrolizumab - 200 mg administered every 3 weeks per package insert. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Name: POH-TMZ Drug: Pembrolizumab Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
Other Name: Keytruda |
|
Experimental: Phase 2a Safety Run-In - NEO212 and Nivolumab
The following primary cancers with uncontrolled metrastases to the brain:
NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Nivolumab - 240 mg administered every 2 weeks per package insert |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Name: POH-TMZ Drug: Nivolumab Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
Other Name: Opdivo |
|
Experimental: Phase 2a Safety Run-In - NEO212 and Stivarga (Regorafenib)
- Colorectal cancer (CRC) with uncontrolled metastases to the brain who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anU-EGFR therapy. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Stivarga - 160 mg orally, once daily for the first 21 days of each 28-day cycle per package insert |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Name: POH-TMZ Drug: Regorafenib Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Other Name: Stivagra |
|
Experimental: Phase 2a Safety Run-In - NEO212 and CarbolaUn (ParaplaUn) + Paclitaxel (Taxol)
- Colorectal cancer (CRC) with uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Carboplatin - 300 mg/m2 IV on day 1 every 4 weeks for 6 cycles per package insert. Paclitaxel - 135mg/m2 IV administered over 24 hours, every 3 weeks per package insert. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Name: POH-TMZ Drug: Carboplatin Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Other Name: Paraplatin Drug: Paclitaxel Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
Other Name: Taxol |
|
Experimental: Phase 2a Safety Run-In - NEO212 and FOLFIRI (Zaltrap) + Bevacizumab (Avastin)
- Metastatic colorectal cancer (mCRC) with uncontrolled metastases to the brain, that is resistant to or has progressed following an oxaliplatin-containing regimen NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. FOLFIRI - 4 mg/kg aIV over 1 hour every 2 weeks. Bevacizumab - 10 mg/kg IV every 2 weeks. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Name: POH-TMZ Drug: FOLFIRI Protocol FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs: FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating. Other Name: Zaltrap Drug: Bevacizumab Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Other Names:
|
|
Experimental: Phase 2b efficacy - NEO212 for Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype
Patients receiving NEO212 alone for treatment of Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Name: POH-TMZ |
|
Experimental: Phase 2b efficacy - NEO212 & SOC for Uncontrolled Metastases to the Brain
Patients receiving NEO212 in combination with select standard of care treatments for treatment of uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. SOC treatments established to be safe in Phase 2a of the study will be used in this arm of Phase 2b. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Name: POH-TMZ Drug: Ipilimumab Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
Other Name: Yervoy Drug: Pembrolizumab Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
Other Name: Keytruda Drug: Nivolumab Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
Other Name: Opdivo Drug: Regorafenib Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Other Name: Stivagra Drug: Carboplatin Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Other Name: Paraplatin Drug: Paclitaxel Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
Other Name: Taxol Drug: FOLFIRI Protocol FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs: FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating. Other Name: Zaltrap Drug: Bevacizumab Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Other Names:
|
- Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain [ Time Frame: 6 months ]As determined by incidence and severity of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0
- Phase 1: Identify the maximum tolerated dose (MTD) of NEO212 [ Time Frame: 6 months ]Maximum Tolerated Dose of NEO212 as determined by the dose escalation rules.
- Phase 1: Determine the recommended Phase 2 dose (RP2D) of NEO212 [ Time Frame: 6 months ]Determine the recommended Phase 2 dose (RP2D) of NEO212
- Phase 2a: Assess the safety and tolerability of orally administered NEO212 in combination with select SOC regimens following a standard 3+3 design in patients with select solid tumors with uncontrolled metastases to the brain [ Time Frame: 6 months ]Determined by incidence and severity of adverse events determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0).
- Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype. [ Time Frame: 6 months ]Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype.
- Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain. [ Time Frame: 6 months ]Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors (see Appendix 2) with uncontrolled metastases to the brain.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Patient must be ≥ 18yrs of age.
- Patient must have the ability to understand, and the willingness to sign, a written informed consent form.
- Patient has been on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.
- Any toxicity from prior therapy must be resolved or at maximum Grade 1 prior to initiation of NEO212.
- If progression of disease occurs within 90 days or conformal radiation, the progression/recurrence must be outside of the radiation field or proven by biopsy/resection.
- Patient with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype must have a Karnofsky Performance Status (KPS) of ≥ 60.
- Patient with select solid tumors must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Patient must have an expected survival or at least three months.
- Patient must have a baseline MRI of the brain with gadolinium within 14 days of administration of NEO212.
- Patient must have a baseline CT scan with IV contrast and oral contrast of neck, chest, abdomen and pelvis within 14 days of administration of NEO212.
- Patients must be able to comply with all study assessments.
- If patient suffers from seizures (s)he must be controlled on a stable dose of anti-epileptics for 14-days prior to the date of informed consent.
- Patient must have adequate organ and marrow function as follows:
- Absolute neutrophil count ≥ 1,500/microliter
- Platelets ≥ 100,000/microliter
- Total bilirubin within normal institutional limits
- AST (SGOT) / ALT (SPGT) ≤ 2.5 x institutional upper limit of normal
- Creatinine clearance (CrCl) of >60 mL/min (using the Cockcroft-Gault formula or 24-hour urine collection).
-
Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.
-
1. A female of child-bearing potential is any women (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time in the preceding 12 consecutive months).
- A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to the receipt of NEO212.
- A serum pregnancy test will be repeated immediately if pregnancy is suspected.
-
Phase 1: (dose escalation)
-
Patient must:
- have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
- have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
-
Patients receiving prior systemic therapy must have a minimum wash-out period (defined as the period prior to receipt of the first dose of NEO212) of:
- 28 days or 5 half-lives (whichever is shorter) elapsed from the administration from any experimental agent;
- 2 weeks from administration of immunotherapies;
- 28 days from administration of cytotoxic agents; and
- 7 days from administration of non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid, and herbal medicine).
NOTE: No washout is necessary for alternating electrical fields.
Phase 2a: (safety run-in)
- Patient must have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
- Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.
- Patient must have measurable/evaluable CNS disease per RANO or RANO-BM criteria.
- Patient must have measurable/evaluable systemic disease per RECIST v1.1 criteria.
Phase 2b: (efficacy)
-
Patient must:
- have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
- have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
- Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.
- Patient must have measurable/evaluable CNS disease per RANO or RANO-BM criteria.
- Patient must have measurable/evaluable systemic disease per RECIST v1.1 criteria.
- Creatinine clearance (CrCl) of >60 mL/min (using the Cockcroft-Gault formula or 24-hour urine collection).Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy
Exclusion Criteria: (all Phases)
- Patient in Phase 1 concurrently receiving any other antitumor therapy.
- Patient in Phase 2a or 2b who is concurrently receiving any SOC therapy not listed in Appendix 1.
- Patients with metastases to the spinal cord parenchyma.
- Patients with metastases to the meninges.
- Patient has had more than one recurrence or progression of his/her CNS tumor(s).
- Patient has received stereotactic or highly conformal radiotherapy to CNS lesions within 2 weeks before receipt of NEO212.
- Patient with history of known leptomeningeal involvement.
- Patient has prior history or new diagnosis of secondary cancer within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin.
- Patient has a corrected QT interval (using Fridericia's correction formula) (QTcF) of > 470 msec, , a history of additional risk factors for TdP (e.g. heart failure, hypokalemia), and/or the use of concomitant medications that prolong QT/QTc interval.
- Patient had surgery within 7 days prior to the date of informed consent.
- Patient has not recovered to Grade 1 from treatment related adverse events due to chemotherapy, immunotherapy, or radiation therapy.
- Patient had prior treatment with perillyl alcohol.
- Patient has a history of allergic reactions attributed to perillyl alcohol.
- Patients with an autoimmune disease that required systemic therapy or a medical condition that requires immunosuppression.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06047379
| Contact: Christopher Beardmore | 224 218 2408 | chris@anovaevidence.com | |
| Contact: Chloe Richmond | 224 218 2408 | chloe@anovaevidence.com |
| United States, California | |
| Precision NextGen Oncology | Recruiting |
| Beverly Hills, California, United States, 90212 | |
| Contact: Mini Gil, MD 424-777-0708 | |
| Principal Investigator: Kamlesh Sankhala, MD | |
| United States, Washington | |
| Northwest Medical Specialties | Recruiting |
| Tacoma, Washington, United States, 98405 | |
| Contact: Sue Quinsey 253-380-8173 | |
| Principal Investigator: Jorge Chaves, MD | |
| Study Chair: | Tom Chen, MD, PhD | NeOnc Technologies | |
| Study Director: | Vincent Simmons, PhD | NeOnc Technologies | |
| Study Director: | Patrick Walters | NeOnc Technologies |
| Responsible Party: | Neonc Technologies, Inc. |
| ClinicalTrials.gov Identifier: | NCT06047379 |
| Other Study ID Numbers: |
NEO212-01 |
| First Posted: | September 21, 2023 Key Record Dates |
| Last Update Posted: | February 14, 2024 |
| Last Verified: | February 2024 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Astrocytoma IDH-mutant Glioblastoma IDH-wildtype Brain Metastases CNS Tumor |
GBM NeOnc Anova NEO212 NEO100 TMZ |
|
Carcinoma, Merkel Cell Carcinoma Neoplasms Lung Neoplasms Colorectal Neoplasms Carcinoma, Squamous Cell Neoplasm Metastasis Glioblastoma Small Cell Lung Carcinoma Brain Neoplasms Astrocytoma Squamous Cell Carcinoma of Head and Neck Esophageal Squamous Cell Carcinoma Microsatellite Instability Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |